Cost-Effectiveness Analysis of Camrelizumab Immunotherapy versus Docetaxel or Irinotecan Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

PURPOSE: The aim of this study was to assess the cost-effectiveness of camrelizumab immunotherapy versus docetaxel or irinotecan chemotherapy as second-line therapy for advanced esophageal squamous cell carcinoma (ESCC), which was evaluated in the ESCORT trial. MATERIALS AND METHODS: A partitioned s...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Ying-Tao, Chen, Ying, Liu, Tian-Xiu, Kuang, Fang, Huang, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572144/
https://www.ncbi.nlm.nih.gov/pubmed/34754242
http://dx.doi.org/10.2147/CMAR.S335515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572144/
https://www.ncbi.nlm.nih.gov/pubmed/34754242
http://dx.doi.org/10.2147/CMAR.S335515

Ejemplares similares